Ali Gohar Pharma (AGPL): IPO fairly priced – By FCEL Research

<ul><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">The wheels of new offerings at the bourse start to roll with Ali Gohar Pharma (AGPL) being the second company in 2018 getting itself listed. </span></li><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">Majority shareholders, OBS Pakistan (Pvt.) Limited and Muller &amp; Phillips Pakistan (Private) Limited intend to offer 35mn shares representing 12.5% of the paid-up capital. The company has 53 products with a strong goodwill established in GYNAE and PAEDS medicine category. </span></li><li><span style="font-family:Arial, Helvetica, sans-serif;font-size:medium;">The revenue of the company has grown at a 5yr CAGR of 12.2% where the company forecasts revenue to increase by 19% over the 7yr period backed by partnership with Mylan...